Summary & Overview
HCPCS Level II E0765: Nerve Stimulator for Treatment of Nausea and Vomiting
HCPCS Level II code E0765 identifies an FDA-approved nerve stimulator used for the treatment of nausea and vomiting. This code captures the provision of a neuromodulation device intended to manage refractory or treatment-resistant nausea/vomiting, an area of growing clinical interest as nonpharmacologic interventions expand. Nationally, device-based therapies can affect utilization patterns in gastroenterology, otolaryngology, and pain management settings and have implications for durable medical equipment and outpatient procedure billing.
Key payers covered in typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical purpose of the device, typical sites of service where the device is supplied or managed, and the billing context for a device-based neuromodulation therapy. The publication also outlines common billing modifiers and payer considerations where available, and summarizes what to expect in payer coverage and coding workflows. Data not available in the input will be noted as such in relevant sections.
Billing Code Overview
HCPCS Level II code E0765 describes an FDA-approved nerve stimulator for treatment of nausea and vomiting. The service represented is the provision of a medical device-based neuromodulation therapy intended to reduce or control symptoms of nausea and vomiting when clinically indicated. Typical site of service is ambulatory clinic or outpatient specialty clinic, and may also include hospital outpatient departments where device evaluation, fitting, or monitoring are performed.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with refractory gastroparesis or intractable nausea and vomiting who has not responded to dietary modification, prokinetic agents, or antiemetic therapy. The patient is evaluated in a gastroenterology clinic, where history, symptoms severity assessment (nausea frequency, vomiting episodes, nutrition status), and prior treatment trials are documented. Diagnostic workup often includes gastric emptying study, metabolic and medication review, and exclusion of mechanical obstruction via imaging or endoscopy.
When conservative therapies fail, the patient is referred for neuromodulation evaluation. A multidisciplinary visit with a gastroenterologist and pain/neuromodulation specialist reviews indications, device mechanism, expected benefits, risks, and candidacy. A temporary trial of an external or transcutaneous nerve stimulator may be performed to assess symptom response. If the trial demonstrates clinically meaningful reduction in nausea and vomiting, implantation of an FDA-approved implantable nerve stimulator for treatment of nausea and vomiting (billing code E0765) is scheduled in an outpatient surgical suite or ambulatory surgery center.
Typical peri-procedure workflow includes preoperative assessment, imaging or ultrasound guidance for lead placement, implantation of the stimulator generator and leads under local anesthesia with sedation or general anesthesia as indicated, intraoperative programming and test stimulation, and postoperative recovery with device education and follow-up programming visits. Follow-up at 1–2 weeks assesses wound healing, then at 4–6 weeks and periodically thereafter for device optimization and monitoring of symptom response and complications.
Coding Specifications
| Modifier | Description |
|---|